Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 1 completed trials

    Completion Rate
    50%(1/2)
    Active Trials
    0(0%)
    Results Posted
    100%(1 trials)
    Terminated
    1(50%)

    Phase Distribution

    Phase 1
    1
    50%
    Phase 2
    1
    50%

    Phase Distribution

    1

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution2 total trials
    Phase 1Safety & dosage
    1(50.0%)
    Phase 2Efficacy & side effects
    1(50.0%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Completed(1)
    Terminated(1)

    Detailed Status

    Completed1
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    50.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 11 (50.0%)
    Phase 21 (50.0%)

    Trials by Status

    completed150%
    terminated150%

    Recent Activity

    0 active trials
    Showing 2 of 2
    terminatedphase_2

    Development of Immune Globulin Treatment for Avian Flu

    NCT00383071
    completedphase_1

    Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

    NCT01443663

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT00383071Phase 2

    Development of Immune Globulin Treatment for Avian Flu

    Terminated
    NCT01443663Phase 1

    Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

    Completed

    All 2 trials loaded

    Drug Details

    Intervention Type
    Biological
    Total Trials
    2